TD Cowen raised the firm’s price target on Ascendis Pharma (ASND) to $160 from $157 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma participates in a conference call with JPMorgan
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Ascendis Pharma Updates Corporate Charter and Capital Structure
- BioMarin price target lowered to $86 from $110 at Barclays
- Ascendis Pharma Seeks FDA Expansion for TransCon hGH